Delaware Group Equity Funds Iv · net assets $750M · 108 holdings as of June 30, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 95.0% · EP: 3.0% · STIV: 2.0%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $43.1M | $14.3M | $15.6M |
| Reinvestment | $0 | $0 | $0 |
| Redemptions | $19.6M | $15M | $12.1M |
| Net realized gain (non-derivative) | $990K | $127K | $301K |
| Net unrealized appreciation (non-derivative) | $961K | $10.7M | $42.8M |
The three months of the reporting period, as filed; month 3 ends June 30, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Ucb Sa EC | $39M | 5.19% |
| Abbvie Inc EC | $31.5M | 4.19% |
| Eli Lilly & Company EC | $31.2M | 4.16% |
| Regeneron Pharmaceuticals Inc EC | $29.3M | 3.91% |
| Unitedhealth Group Inc EC | $29.1M | 3.88% |
| Pfizer Inc EC | $28.8M | 3.84% |
| Merck & Company Inc EC | $27.6M | 3.68% |
| Gilead Sciences Inc EC | $26.5M | 3.54% |
| Astrazeneca PLC EC | $24.5M | 3.27% |
| Elevance Health Inc EC | $24.4M | 3.25% |
| Roche Holding Ag EP | $22.6M | 3.01% |
| Chugai Pharmaceutical Co Ltd EC | $20.8M | 2.77% |
| Viatris Inc EC | $18.6M | 2.48% |
| Oruka Therapeutics Inc EC | $18.1M | 2.41% |
| Halozyme Therapeutics Inc EC | $17.2M | 2.30% |
| Amgen Inc EC | $17M | 2.27% |
| Illumina Inc EC | $15.8M | 2.11% |
| Alkermes PLC EC | $13.6M | 1.82% |
| Viking Therapeutics Inc EC | $12.9M | 1.72% |
| Vertex Pharmaceuticals Inc EC | $12.4M | 1.66% |
| Roivant Sciences Ltd EC | $12M | 1.60% |
| Neurocrine Biosciences Inc EC | $11.8M | 1.57% |
| Arcus Biosciences Inc EC | $11.7M | 1.56% |
| Zimmer Biomet Holdings Inc EC | $10.7M | 1.42% |
| Boston Scientific Corp EC | $10.7M | 1.42% |
| Sanofi Sa EC | $10.3M | 1.37% |
| Uniqure Nv EC | $10M | 1.34% |
| Stryker Corp EC | $9.45M | 1.26% |
| Incyte Corp EC | $9.07M | 1.21% |
| Alnylam Pharmaceuticals Inc EC | $9.03M | 1.20% |
| Cogent Biosciences Inc EC | $8.9M | 1.19% |
| Federal National Mortgage Association EC | $8.46M | 1.13% |
| Medtronic PLC EC | $7.82M | 1.04% |
| Cvs Health Corp EC | $7.76M | 1.03% |
| Abbott Laboratories EC | $7.26M | 0.97% |
| Quest Diagnostics Inc EC | $6.36M | 0.85% |
| Anaptysbio Inc EC | $6.33M | 0.84% |
| Tarsus Pharmaceuticals Inc EC | $6.29M | 0.84% |
| Federal Home Loan Mortgage Corp EC | $6.28M | 0.84% |
| Rigel Pharmaceuticals Inc EC | $6.26M | 0.83% |
| Biogen Inc EC | $6.05M | 0.81% |
| Grail Inc EC | $5.8M | 0.77% |
| Biomarin Pharmaceutical Inc EC | $5.72M | 0.76% |
| Vir Biotechnology Inc EC | $5.1M | 0.68% |
| Johnson & Johnson EC | $5.08M | 0.68% |
| Monte Rosa Therapeutics Inc EC | $4.84M | 0.65% |
| Immunovant Inc EC | $4.7M | 0.63% |
| Abivax Sa EC | $4M | 0.53% |
| Syndax Pharmaceuticals Inc EC | $3.93M | 0.52% |
| Madrigal Pharmaceuticals Inc EC | $3.76M | 0.50% |
| Fidelity Colchester Street Trust STIV | $3.67M | 0.49% |
| Goldman Sachs Trust STIV | $3.67M | 0.49% |
| Morgan Stanley Institutional Liquidity Funds STIV | $3.67M | 0.49% |
| Blackrock Liquidity Funds STIV | $3.67M | 0.49% |
| Theravance Biopharma Inc EC | $3.55M | 0.47% |
| Xencor Inc EC | $3.22M | 0.43% |
| Structure Therapeutics Inc EC | $3.11M | 0.41% |
| Perrigo Co PLC EC | $2.39M | 0.32% |
| Acadia Pharmaceuticals Inc EC | $2.34M | 0.31% |
| Ultragenyx Pharmaceutical Inc EC | $2.34M | 0.31% |
Showing top 60 of 108 holdings.
Loading...
